Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 20/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12462209 | 1.00 | ITGA4 (0.62) | ITGA4 | |
| SCHEMBL12166629 | 1.00 | ITGA4 (0.62) | ITGA4 | |
| SCHEMBL12446688 | 1.00 | ITGA4 (0.62) | ITGA4 | |
| SCHEMBL6742913 | 0.92 | ITGA4 (0.61) | ITGA4 | |
| SCHEMBL7263867 | 0.91 | ITGA4 (0.56) | ITGA4 | |
| SCHEMBL7110234 | 0.91 | ITGA4 (0.56) | ITGA4 | |
| SCHEMBL7115955 | 0.91 | ITGA4 (0.56) | ITGA4 | |
| SCHEMBL6743975 | 0.91 | ITGA4 (0.60) | ITGA4 | |
| SCHEMBL6740927 | 0.91 | ITGA4 (0.60) | ITGA4 | |
| SCHEMBL6742917 | 0.91 | ITGA4 (0.55) | ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309579-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-11-13 | — | — | US | disclosed |
| US-8309579-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-11-13 | — | — | US | disclosed |
| US-8198280-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-06-12 | — | — | US | disclosed |
| US-8198280-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-06-12 | — | — | US | disclosed |
| US-20110281891-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110281891-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | MERCK SERONO SA (CH) | 2011-11-17 | — | — | US | disclosed |
| US-7998964-B2 | hydroxy((2S)-2-{[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl}-4-methylpentyl)formamide ; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative disorders, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO S.A. (CH) | 2011-08-16 | — | — | US | disclosed |
| US-7998964-B2 | hydroxy((2S)-2-{[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl}-4-methylpentyl)formamide ; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative disorders, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO S.A. (CH) | 2011-08-16 | — | — | US | disclosed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | disclosed |
| US-7973039-B2 | 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors | MERCK SERONO SA (CH) | 2011-07-05 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| WO-2007060132-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007048788-A1 | SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES | LABORATOIRES SERONO S.A. (CH) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007009959-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006079653-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | LABORATOIRES SERONO S.A. (CH) | 2006-08-03 | — | — | WO | disclosed |
| US-20050222193-A1 | Novel combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-10-06 | — | — | US | disclosed |
| US-20050165041-A1 | Combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1089989-A1 | INHIBITORS OF ALPHA4BETA1 MEDIATED CELL ADHESION | PHARMACIA & UPJOHN COMPANY (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067230-A1 | INHIBITORS OF α4β1 MEDIATED CELL ADHESION | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | MGLL, MBOAT4, MBOAT1 | ITGA4 4183/4885 |
| US-20110281891-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | ITGA4 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.